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Introduction
Stroke is the 2nd most common cause of death and the 3rd most 
common cause of disability worldwide [1]. Daily, many stroke patients 
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Abstract
Stroke patients have an uncertain prognosis. It has been postulated that biomarkers’ concentrations upon 
admission could be linked to the neurological outcome. This meta-analysis reviewed the literature and collected data 
for 65 biomarkers. To increase power of evidence, only biomarkers who were: 
• Significant in the meta-analysis,
• Reported by two or more studies conducted by different authors,
• Displaying more than 300 patients and
• Displaying less or equal to 60% heterogeneity were retained.
Eight biomarkers were found to be relevant; TNFα, white blood cell count, non-fasting glucose, GPT, D-dimer,
fT3, cortisol and MRproANP. These except for GPT and fT3 show the same trend: a low concentration at admission 
is linked to a good outcome. For GPT and fT3 the reverse was observed; a low concentration in the acute phase 
was linked to an adverse outcome. Early biomarker analysis would help the physician to determine the extent of the 
neurological deficit in stroke patients. This can guide them to implement new treatment strategies such as intensive 
rehabilitation or a more aggressive treatment.
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are admitted to the emergency room (ER), their prognosis remains 
uncertain. A stroke’s outcome is estimated through various clinical 
variables. Stroke severity upon admission is the most important 
predictive factor. The more severe the neurological impairment, the 
more likely the chance of an adverse outcome [2]. The extent of the 
neurological deficits at admission is usually measured by the National 
Institute of Health Stroke Scale (NIHSS). Scores range from 0 to 42 
with 0 representing no neurological impairment, 42 representing the 
most severe stroke possible [3]. Other predictors of adverse outcomes 
are advanced age (>65 years), previous stroke, peripheral artery 
disease, increasing time between onset and admission and diabetes 
[4,5]. There are two subtypes of stroke: ischemic strokes (IS) and 
haemorrhagic strokes (HS). An IS occurs when the blood supply to a 
part of the brain is interrupted or insufficient. They account for 80% of 
strokes. A HS occurs when a blood vessel is ruptured and represents 
20% of all strokes [6]. HS are usually more severe than IS and have 
worse survival rates [7]. Complications may further aggravate a 
patient’s functional prognosis, such as haemorrhagic transformation 
(a known complication following recombinant tissue plasminogen 
activator (rtPA) therapy), fluid depletion, hyper- or hypoglycemia 
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In stroke survivors most recovery occurs in the first six months 
though improvement may be observed up until 18 months [5]. Some 
sources state that regain of function can occur till 2 years after a stroke 
[2]. 40% to 60% of all stroke patients regain functional independence 
between 3 months and 10 years [5]. 44% of stroke survivors report no 
or light disabilities. This means that more than half of stroke victims 
suffer medium to severe disabilities. These range from physical 
problems e.g. hemiparesis, difficulty speaking, reduced cognitive 
capacity to emotional difficulties [2]. The modified Rankin Scale (mRS) 
is used to depict a patient’s capabilities and handicaps after a stroke 
insult. This score ranges from 0 to 6. Scores from 0-2 means the patient 
is independent in activities of daily living; 3-5 depicts dependence in 
daily life, 6 represents death [8].
Some authors have studied clinical variables (such as age, sex, 
comorbidities, etc.) and their relation to the outcome [9]. Others 
have implemented these clinical variables into predictive models and 
both studies found age and severity of stroke to be associated with 
the outcome and suitable for use in a predictive model [10,11]. Reid 
included other variables such as ability to lift both arms, pre-stroke 
ability, ability to walk independently etc. and found that these variables 
improved the predictive capabilities of their model [10]. Swarowska 
attempted to improve their predictive model based on stroke severity 
and age by addition of fibrinogen levels. They did not find that this 
addition significantly increased the discrimination ability of their 
model [11]. This further proves that, although there is evidence that 
biomarkers correlate to the outcome, actually implementing biomarkers 
into predictive models remains a challenge due to conflicting results 
[10,12,13].
Our meta-analysis will highlight the most important biomarkers 
analysed upon admission and correlate them with the patient’s 
prognosis. Also, we highlight which early biomarkers could be of 
interest in a clinical setting.
Methodology
The literature of the last six years was analysed using the MeSH 
terms ‘stroke, ‘prognosis’ and ‘biomarkers’ on Pubmed. Only studies 
published between 01/01/210 and 01/01/2017 in English pertaining 
human subjects were considered. Articles were excluded if they focussed 
on the effect of a therapy or intervention, used death as the primary 
outcome instead of neurological prognosis, focused on cardiovascular 
events other than stroke, focused on the pathogenesis of a stroke or 
were reviews, case reports or study protocols. In Figure 1, the flow 
chart of the literature selection is shown as are the exclusion criteria. 











♦   Not published in English, Dutch or 
French 
♦   Not published between 01/01/2010 
and 01/01/2017 
♦   Animal studies 
Articles selected for meta-analysis (n=121) 
Remaining articles after applying Pubmed 
filters (n=543) 
Articles whose data was available (n=37) 
     
Excluded (n=422) based on inclusion 
criteria 
♦   Focusing on therapy or intervention 
♦   Focusing on death as the primary 
outcome 
♦   Focusing on other cardiovascular 
events 
♦     Focusing on prediction or prevention 
of a stroke 
♦     Focusing on the pathogenesis 
♦     Reviews, case reports and study 
protocols 
 
Studies identified from database Pubmed 
(n=854) 
Articles who did not publish their data (n=84) 
Figure 1: Literature search.
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yet many did not have their data available. In total 37 studies were 
included in the meta-analysis, highlighting 65 different biomarkers. 
From all eligible reports, data was extracted and input into Revman 
5.3 for further analysis. Two groups of patients were defined; good 
outcome and poor outcome patients. These groups were divided based 
on NIHSS score or mRS score. The cut-off value of the NIHSS score 
was usually set at 12, with the group having a score of 12 or more being 
defined as the poor outcome group. When using the mRS, patients with 
a score of 3 or higher were defined as the adverse outcome group. Mean 
biomarker’s concentrations at admission were compared between 
these groups. When the median and IQR were reported instead of the 
mean and SD, the method suggested by Wan was used to derive the 
mean and SD [14].
Because of the limited number of patients included in different 
studies, extra criteria for significance were applied in this meta-analysis 
to increase power of evidence. Only the biomarkers that were 
• Significant in the meta-analysis, 
• Reported in two or more studies analysed by different authors, 
• Displaying a large number of patients (300 or more) and 
• Displaying a mild amount of heterogeneity (≤ 60% defined by 
the Cochrane Handbook) was considered significant [15]. 
A biomarker was considered statistically significant if the P-value 
was equal to or less than 0.05.
Results
All 65 biomarkers were further divided into different groups to 
facilitate reporting. These categories are; inflammatory biomarkers, 
metabolic biomarkers, haemostatic biomarkers, endocrine biomarkers, 
neuronal biomarkers, astroglial biomarkers, anti-apoptotic biomarkers 
and anti-angiogenic biomarkers. This method of reporting was based 
on Park [16].
Table 1 is an overview of all biomarkers per category. This table 
includes the studies references, sample size, heterogeneity and P-value 
per biomarker. 
Figure 2 displays a forest plot of all biomarkers which remained 
significant after applying the four extra criteria. From this forest plot 
the nature of the association between a biomarker’s measure and the 
neurological outcome can be derived.
Inflammatory biomarkers
In this group, C-reactive protein (CRP), high-sensitive C-reactive 
protein (hsCRP), interleukin-6 (IL-6), interleukin-8 (IL-8), 
interleukin-10 (IL-10), matrix metalloproteinase 9 (MMP-9), tumor 
necrosis factor α (TNFα), osteopontin (OPN), procalcitonin (PCT), 
cluster of differentiation 40 ligand (CD40L); homocysteine (HCY), 
white blood cell count (WBC), high-mobility-group box-1 (HMGB-1), 
growth differentiation factor 15 (GDF-15), monocyte chemoattractant 
protein 1 (MCP-1) and monocyte count were reported. As it is showed 
in Table 1; CRP, hsCRP, IL-10, TNFα, PCT, HCY, WBC, HMGB-1 and 
GDF-15 were significantly correlated with the outcome. CRP, hsCRP, 
IL-6, MMP-9 HCY, GDF-15 all had a heterogeneity of more than 
60%. IL-8, IL-10, OPN, Procalcitonin, CD40L, HMGB-1, MCP-1 and 
monocytes were reported in only one study. After applying the extra 
criteria only TNFα and WBC remained significant. Both biomarkers 
are depicted in Figure 2. As it can be seen in the forest plot; a low 
concentration of these biomarkers at admission was associated with a 
good neurological outcome.
Metabolic biomarkers
Here total cholesterol (TC), triglycerides (TG), low-density 
lipoprotein-cholesterol (LDL-c), high density lipoprotein- cholesterol 
(HDL-c), fasting glucose, non-fasting glucose, uric acid, adiponectin, 
creatinine, lipoprotein a (Lp(a)), glutamate, calcium, magnesium, 
potassium, bilirubin, glutamate-oxaloacetate transaminase (GOT), 
glutamate-pyruvate transaminase (GPT) and blood urea nitrogen 
(BUN) were analysed. Glucose (both fasting and non-fasting), Lp 
(A), glutamate, magnesium, potassium and GPT were statistically 
significant. When applying the four criteria, only non-fasting glucose 
and GPT remained. The analysis of fasting glucose showed a large 
amount of heterogeneity. The other significant biomarkers were 
reported in but one study. Figure 2 depicts both non-fasting glucose 
and GPT. A low concentration of non-fasting glucose at admission was 
associated with a good neurological outcome. However, when GPT 
concentration was low a poor neurological prognosis was observed.
Haemostatic biomarkers
In this group fibrin degradation products (FDP), fibrinogen, 
D-dimer, plasminogen activator inhibitor-1 (PAI-1), tissue 
plasminogen activator (tPA), platelet count and procarboxypeptidase 
U (proCPU) were evaluated. Both FDP and D-dimer were statistically 
significant however FDP is reported in only one study. D-dimer 
showed a clear association with the outcome; a low concentration was 
linked to a good outcome.
Endocrine biomarkers
Thyroid stimulating hormone (TSH), ratio of thriiodothyronine 
and free thryoxine (T3/fT4), thriiodothryonine (T3), free 
thriiodothryonine (fT3), free thryroxine (fT4), ratio of 
thriiodothyronine and free thryoxine T3/fT4, growth hormone (GH), 
insulin-like growth factor-1 (IGF-1), cortisol, 25-hydroxyvitamin D 
(25(OH)D), copeptin, brain natriuretic peptide (BNP), N-terminal 
prohormone of BNP (NTproBNP) and midregional pro-atrial 
natriuretic peptide (MRproANP) were evaluated. These biomarkers 
except for TSH, fT3/T4, fT4 and GH were significant. T3, T3/fT4, 
IGF-1, 25(OH)D, BNP and NTproBNP were all reported in only one 
study. Copeptin’s analysis contains too much heterogeneity (I2=81%). 
Only fT3, cortisol and MRproANP fulfil all extra criteria. As showed in 
Figure 2, low concentrations of fT3 were linked to a bad neurological 
outcome. Low concentrations of cortisol and MRproANP however 
were linked to a good neurological outcome.
Neuronal biomarkers
Neuron specific enolase (NSE) in serum, neuroglobin (NgB) and 
heart-type fatty acid binding protein (hFABP) were reported in this 
group with statistical significance reached for NgB and hFABP. These 
were only reported in one study and could not fulfil the extra criteria.
Astroglial biomarkers
S100 calcium binding protein β (S100β) as a biomarker was analysed 
in this subgroup. This biomarker reached statistical significance but 
because of its small size, it was excluded.
Anti-apoptotic biomarkers
In this category five biomarkers were analysed: thioredoxin, heat 
shock protein 27 (HSP-27), microRNA 16 (miR-16), microRNA 124-3p 
(miR-124-3p) and progranulin (PRGN). Thioredoxin and PRGN reach 
statistical significance in our meta-analysis, but both were reported in 
one study and therefore were not retained. 
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Anti-angiogenic biomarkers
Endostatin was statistically significant but only reported in one 
study. In conclusion TNFα, WBC, non-fasting glucose, GPT, D-dimer, 
fT3, cortisol and MRproANP could be related to stroke outcome. These 
except GPT and fT3 showed the same trend; a low concentration was 
linked to a good neurological outcome. For GPT and fT3 a reverse 
association was seen; a low concentration at admission was linked to a 
bad neurological outcome. Generally, the strongest evidence presents 
itself for non-fasting glucose. This biomarker is reported in eight 
different studies conducted by different authors, has a sample size of 
2218, a heterogeneity of 0% and a P-value of less than 0.00001.
Figure 2: Forest plot of biomarkers.
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Discussion
A low mean concentration of TNFα was associated with a good 
neurological outcome (Figure 2). Park and Zeng measured the outcome 
at three months, based on the mRs [16,17]. Chang measured the 
outcome at 48h through the use of the NIHSS [18]. A review by Laborde 
also found a link between low concentrations of TNFα at admission and 
good outcomes, further strengthening our conclusions [19]. A possible 
explanation for this association is that inflammation following brain 
ischemia upregulates cytokines and chemokines leading to secondary 
brain damage. TNFα is closely related to these upregulated molecules 
and can further increase their detrimental effects [17]. Interesting 
to mention is that Rothstein noticed a possible link between a high 
concentration of TNFα and Early Neurological Deterioration (END). 
END being defined as worsening of the neurological status 48-72 h after 
admission [12]. END can possibly be linked to a worse clinical outcome 
[20]. The question remained if TNFα is linked to the prognosis or 
linked to END, which could in turn complicate the patient’s outcome. 
In our meta-analysis, a low WBC count was linked to a better 
outcome. Four studies measured the outcome at three months, but 
could not confirm a link with the prognosis in their own analyses 
[21-24]. In the studies that did reach significance, two measured the 
outcome at three months, one at discharge and one at 48 h [16,18,24,25]. 
The difference in time of end points cannot explain the discrepancies in 
conclusions between the studies. Furthermore, a study by Zhou whose 
data could not be included also found high WBC counts to be associated 
with a bad outcome [26]. Another study conducted by Tsai did not 
look into the relation between WBC counts and the outcome but did 
find that WBC counts are linked to major adverse clinical outcomes 
(MACO; recurrent stroke or death) [27]. The question remains in this 
case whether WBC counts are merely a risk indicator of MACO or if 
they are in fact related to the outcome, independent from a recurrent 
stroke.
A lower concentration of non-fasting glucose was linked to a good 
outcome. Hasan concluded in their report that high levels of glucose 
were a strong predictor for poor outcome following an ischemic 
stroke [28]. Another study from 2015 by Masrur found that both acute 
and chronic hyperglycemia were associated with worse post-stroke 
outcome, regardless whether diabetes was diagnosed before occurrence 
of the stroke or not [29]. Both studies reached the same conclusion as 
this meta-analysis. What should be considered is that this biomarker is 
severely influenced by the patient’s last meal but also by their level of 
insulin resistance. This resistance could in turn be part of the etiology 
of a stroke and cause hyperglycemia which ultimately could exacerbate 
the stroke [30,31]. In our meta-analysis, the most robust evidence was 
collected for this biomarker. 
Low GPT concentrations were significantly associated with a bad 
stroke outcome in our meta-analysis. Both studies were independently 
significant. Both measured the outcome at three months [21,32]. It can 
be assumed that low GPT concentrations at admission predict a bad 
neurological outcome at three months post stroke. However, no studies 
researched the link between GPT and the outcome at other points and 
as such this remains an assumption. GPT metabolizes glutamate in the 
peripheral blood, possibly reducing the risk of excitotoxicity [21,33]. In 
rats, GPT was proven to exert neuroprotective effects due to breakdown 
of glutamate in the peripheral blood [34,35]. 
D-dimer was the only biomarker significant in the group of 
the haemostatic biomarkers. As can be observed in the forest plot, 
three studies were significant and independently associated with the 
outcome, the study by Zeng was not. This study measured the outcome 
at three months [17]. Wang measured the mRS at one month post 
stroke, the other two significant studies also measured the outcome at 
three months [16,32,36]. A study by Matsumoto whose data could not 
be included found a link between low D-dimer concentrations and a 
good outcome at discharge. They did not mention the length of stay 
in the hospital [37]. The discrepancy in individual findings cannot be 
explained by different measuring points in time. Interesting to note is 
that Yuan analysed the D-dimer levels between the different subtypes 
of strokes and found that this biomarker most clearly relates to strokes 
of cardio-embolic origin. They also concluded that low D-dimer 
levels correlate with a better prognosis [38]. This further supports our 
conclusion. 
Low fT3 concentrations were linked to poorer outcome. Both 
included studies reached significance [39,40]. Ambrosius split 377 
patients into tertiles based on fT3 levels; ≤ 1.95 pg/mL, >1.95 pg/mL 
and <2.47 pg/mL and ≥ 2.47pg/mL. Patients in the lowest tertile had a 
worse outcome at 30 days and one year compared to the average and 
high fT3 groups. The study did not mention the outcome of the first or 
third tertile compared to the second tertile [41]. A recent study by Liu 
found a link between low fT3 levels and a poorer outcome at discharge 
[42]. Ma found that fT3 negatively correlates to CRP and the NIHSS 
and positively correlates to albumin concentrations. They postulate 
that fT3 might be involved in the inflammatory process following a 
stroke and might be able to predict stroke severity [43]. This could 
suggest that fT3 is linked to other inflammatory biomarkers, but is not 
an independent biomarker by itself. 
A lower cortisol concentration at admission is associated with a 
good outcome. All three included studies measured the outcome at 
three months [32,44,45]. Low cortisol levels are possibly linked to a 
good outcome at three months. Reports by Katan and Bustamante 
came to the same conclusion as in our meta-analysis [46,47]. A review 
by Barugh found that cortisol levels should be linked to the patient 
dependency, morbidity and mortality but they emphasized that it is 
not clear whether cortisol relates to these outcomes or relates to the 
initial stroke severity [48]. Cortisol is a stress-related hormone, and 
may reflect the degree of severity of the cerebral insult and hence the 
neurological outcome. Stroke severity is known to be a good predictor 
of the outcome [5].
We found that a lower MRproANP concentration at admission was 
linked to a good outcome [49,50]. Bustamante supports our finding 
[47]. A review by Katan found that a low concentration of MRproANP 
was a good biomarker for a favourable outcome and notices that 
MRproANP was proportionally more elevated in strokes of cardio-
embolic origin than in other subtypes [46]. These support our findings. 
A prospective cohort study concluded that people with an elevated 
MRproANP are at a higher risk to experience a cardio-embolic stroke. 
The risk of other stroke subtypes is not elevated [51]. MRproANP is a 
precursor hormone of atrial natriuretic peptide (ANP) which regulates 
blood pressure [52]. 
Prognostication is paramount in ER. Early biomarkers analysis 
would help the physician to determine the extent of the neurological 
deficit in stroke patient and hence guiding them to implement 
new treatment strategies such as intensive rehabilitation or a more 
aggressive treatment. Also valid biomarkers could be implemented into 
predictive models and to further delignate the type of stroke.
Conclusion
We can conclude that many biomarkers in the literature were 
proposed as being relevant, however only a very few were significant 
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or provide enough evidence. The evidence was most robust for 
TNFα, WBC, non-fasting glucose, GPT, D-dimer, fT3, cortisol and 
MRproANP. Especially non-fasting glucose stands out due to its strong 
evidence. Some other biomarkers such as CRP, though frequently 
reported, failed to confirm their association in our meta-analysis. These 
biomarkers are associated to the neurological prognosis however many 
studies individually did not reach statistical significance. Not all of these 
discrepancies can be caused by population bias, small sample sizes or 
different end points in time and therefore more research is needed.
Future research should focus on reporting the biomarkers in 
categories of low, medium and high concentrations and correlating 
these to the outcome of the patients. This might be more adequate 
in finding a potential link between concentration and outcome. 
Trials should further focus on biomarkers’ temporal profiles and the 
consequences thereof for the predictive model. Follow-up of patients 
should be longer. Ultimately a follow-up at three months, six months 
and one year would be ideal to fully determine a biomarker’s predictive 
capacities.
Finally, more research is needed before we can fully understand 
the link between biomarkers and the stroke prognosis. The eight 
biomarkers found in our meta-analysis should each be re-evaluated 
with special attention to non-fasting glucose.
Limitations
This meta-analysis was a non-exhaustive review of the literature, 
only the last six years were evaluated. Extending the period might 
increase the number of articles, and hence the relevance and the 
significance. Only 37 clinical trials could be included because several 
trials did not publish their data. 
This paper included both IS and HS but made no differentiation 
between them in the meta-analysis. Because of their inherent differences 
in etiology, splitting these would’ve further provided more robust 
evidence and perhaps more clear findings for certain biomarkers. Few 
articles however analysed HS and as such the influence on the results 
would be limited. 
Articles reported neurological impairment usually through use 
of the mRS scale and NIHSS scale. The NIHSS scale however is more 
Biomarker (references) Sample size Heterogeneity P-value
Inflammatory
CRP [16,32,39,53,54] 776 87% 0.0002
hsCRP [23,32] 501 88% 0.003
IL-6 [16,17,55] 697 92% 0.23
IL-8 [17] 105 - 0.08
IL-10 [18] 135 - 0.00001
MMP-9 [16,56] 263 96% 0.68
TNFα [16-18] 415 0% 0.01
OPN [57] 130 - 0.33
Procalcitonin [58] 378 - 0.00001
CD40L [17] 105 - 0.11
HCY [23,32] 501 88% 0.0002
WBC [16,18,21-25] 1755 43% 0.001
HMGB-1 [59] 338 - 0.00001
GDF-15 [54,55] 321 67% 0.03
MCP-1 [60] 30 - 0.62
Monocytes [60] 30 - 0.86
Metabolic
TC [23,25,32,54,59,61,62] 3211 34% 0.12
TG [28-30,36,38,39,41] 3211 14% 0.59
LDL-c [16,32,54,59,61,62] 2801 0% 0.79
HDL-c [23,32,54,59,61,62] 2672 61% 0.05
Fasting glucose [16,62] 1668 67% 0.04
Non-fasting glucose 
[22,23,25,32,57,59,61,63] 2218 0% 0.00001
Uric acid [32,63] 378 0% 0.51
Adiponectin [64] 82 - 0.42
Creatinine [16,18,32,63] 962 55% 0.82
Lp(a) [25] 153 - 0.00001
Glutamate [21] 347 - 0.00001
Calcium [62] 1493 - 0.20
Magnesium [62] 1493 - 0.005
Potassium [62] 1493 - 0.02
Bilirubin [65] 44 - 0.24
GOT [21,32] 554 94% 0.05
GPT [21,32] 554 0% 0.0001
BUN [32] 189 - 1.00
Haemostatic
FDP [17] 105 - 0.01
Fibrinogen [17,22,25,32,61] 1080 92% 0.10
D-dimer [16,17,32,36] 1642 60% 0.0005
PAI-1 [16,17] 280 86% 0.31
t-PA [17] 105 - 0.98
Platelets [21,22,24,25] 1133 59% 0.80
Decrease proCPU [66] 136 - 0.17
Endocrine
TSH [39,40,44] 767 86% 0.75
fT3/fT4 [39] 88 - 0.08
T3 [44] 281 - 0.0001
fT3 [39,40] 486 16% 0.01
fT4 [39,40,44] 767 0% 0.32
T3/fT4 [44] 281 - 0.02
GH [44,67] 321 33% 0.07
IGF-1 [68] 168 - 0.00001
Cortisol [32,44,45] 693 59% 0.00001
25(OH)D [69] 326 - 0.00001
Table 1: Overview of biomarkers.
Copeptin [22,32,70] 650 81% 0.00001
BNP [32] 189 - 0.00001
NTproBNP [32] 189 - 0.0003
MRproANP [49,50] 4002 0% 0.00001
Neuronal
NSE [16] 175 - 0.11
NgB [16] 175 - 0.0001
hFABP [16] 175 - 0.00001
Astroglial
S100β [16,55] 232 0% 0.00001
Anti-apoptotic
Thioredoxin [23] 312 - 0.00001
HSP-27 [71] 123 - 0.56
mi-R16 [72] 84 - 0.19
miR-124-3p [72] 84 - 0.52
PRGN [73] 216 - 0.00001
Anti-angiogenic
Endostatin [74] 109 - 0.003
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suitable for evaluating the stroke severity; less so for the prognosis. 
Also, these scales are inherently difficult to assess and as such may 
introduce some bias. Other articles also included the fatal cases in their 
poor outcome group, other studies did not.
Financial Disclosure/Acknowledgement
The authors have no relevant affiliations or financial involvement 
with any organization or entity with a financial interest in or financial 
conflict with the subject matter of materials discusses in the manuscript. 
This includes employment, consultancies, honoraria, stock ownership 
or options, expert testimony, grants or patents received or pending, or 
royalties.
References
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. (2010) Global and 
regional mortality from 235 causes of death for 20 age groups in 1990 and 
2010. Global Burden of Disease Study 380: 2095-2128.
2. Kuks JB, Snoek JW (2016) Leerboek Klinische Neurologie. Bohn Stafleu van 
Longhum.
3. Kwah LK, Diong J (2014) National Institutes of Health Stroke Scale (NIHSS). 
J Physiother 60: 61.
4. Vogt G, Laage R, Shuaib A, Schneider A (2012) Initial lesion volume is an 
independent predictor of clinical stroke outcome at day 90. Virtual International 
Stroke Trials Archive (VISTA) 43: 1266-1272.
5. Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, et al. (2007) Rate, degree, and 
predictors of recovery from disability. Ischemic Stroke Neurology 68: 1583-1587.
6. Kumar P, Clark M (2012) Clinical Medicine. Saunders Elsevier.
7. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP (2009) Hemorrhagic 
and ischemic strokes compared: Stroke severity, mortality, and risk factors. 
Stroke 40: 2068-2072.
8. Sulter G, Steen C, De Keyser J (1999) Use of the Barthel index and modified 
Rankin scale in acute stroke trials. Stroke 30: 1538-1541.
9. Ojagbemi A, Owolabi M (2013) Predictors of functional dependency after stroke 
in Nigeria. J Stroke Cerebrovasc Dis 22: e381-387.
10. Reid JM, Dai D, Christian C, Reidy Y, Counsell C, et al. (2012) Developing 
predictive models of excellent and devastating outcome after stroke. Age 
Ageing 41: 560-564.
11. Swarowska M, Ferens A, Pera J, Slowik A, Dziedzic T (2016). Can Prediction 
of Functional Outcome after Stroke Be Improved by Adding Fibrinogen to 
Prognostic Model. J Stroke Cerebrovasc Dis 25: 2752-2755.
12. Rothstein L, Jickling GC (2013) Ischemic stroke biomarkers in blood. Biomark 
Med 7: 37-47.
13. Simats A, García BT, Montaner J (2016) Neuroinflammatory biomarkers: From 
stroke diagnosis and prognosis to therapy. Biochim Biophys Acta 1862: 411-424.
14. Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and 
standard deviation from the sample size, median, range and/or interquartile 
range. BMC Med Res Methodol 14: 135.
15. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of 
Interventions: Version 5.1.0. (5thedn). The Cochrane Collaboration.
16. Park SY, Kim J, Kim OJ, Kim JK, Song J, et al. (2013) Predictive value of 
circulating interleukin-6 and heart-type fatty acid binding protein for three 
months clinical outcome in acute cerebral infarction: multiple blood markers 
profiling study. Crit Care 17: 45.
17. Zeng L, Liu J, Wang Y, Wang L, Weng S, et al. (2013) Cocktail blood 
biomarkers: prediction of clinical outcomes in patients with acute ischemic 
stroke. Eur Neurol 69: 68-75.
18. Chang LT, Yuen CM, Liou CW, Lu CH, Chang WN, et al. (2010) Link between 
interleukin-10 level and outcome after ischemic stroke. Neuro Immuno 
Modulation 17: 223-228.
19. Laborde CM, Mourino AL, Akerstrom F, Padial LR, Vivanco F, et al. (2012) 
Potential blood biomarkers for stroke. Expert Rev Proteomics 9: 437-449.
20. Kwon HM, Lee YS, Bae HJ, Kang DW (2014) Homocysteine as a predictor of 
early neurological deterioration in acute ischemic stroke. Stroke 45: 871-873.
21. Campos F, Rodríguez YM, Castellanos M, Arias S, Pérez MM, et al. (2011) 
Blood levels of glutamate oxaloacetate transaminase are more strongly 
associated with good outcome in acute ischaemic stroke than glutamate 
pyruvate transaminase levels. Clin Sci (Lond) 121: 11-17.
22. Dong X, Tao DB, Wang YX, Cao H, Xu YS, et al. (2013) Plasma copeptin levels 
in Chinese patients with acute ischemic stroke: a preliminary study. Neurol Sci 
34: 1591-1595.
23. Qi A, Li Y, Liu Q, Si JZ, Tang XM, et al. (2015) Thioredoxin is a novel diagnostic 
and prognostic marker in patients with ischemic stroke. Radic Biol Med 80: 
129-135.
24. Carbone F, Satta N, Montecucco F (2016) Anti-ApoA-1 IgG serum levels 
predict worse poststroke outcomes. Eur J Clin Invest 46: 805-817.
25. Zhang B, Gao C, Yang N, Zhang W, Song X, et al. (2010) Is elevated SUA 
associated with a worse outcome in young Chinese patients with acute cerebral 
ischemic stroke. BMC Neurol 10: 82.
26. Zhou J, Wu J, Zhang J, Xu T, Zhang H, et al. (2015) Association of stroke clinical 
outcomes with coexistence of hyperglycemia and biomarkers of inflammation. J 
Stroke Cerebrovasc Dis 24: 1250-1255.
27. Tsai TH, Chen YL, Lin HS, Liu CF, Chang HW, et al. (2012) Link between 
lipoprotein-associated phospholipase A2 gene expression of peripheral-blood 
mononuclear cells and prognostic outcome after acute ischemic stroke. J 
Atheroscler Thromb 19: 523-531.
28. Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P (2012) Towards the 
identification of blood biomarkers for acute stroke in humans: a comprehensive 
systematic review. Br J Clin Pharmacol 74: 230-240.
29. Masrur S, Cox M, Bhatt DL, Smith EE, Ellrodt G, et al. (2015) Association of 
Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-
Thrombolysis: Findings From Get With The Guidelines-Stroke. J Am Heart 
Assoc 4: e002193.
30. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, et al. (1998). Leukocyte-
endothelial interaction is augmented by high glucose concentrations and 
hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101: 1905-1915.
31. Baumgartner PSM, Wagner L, Pettermann M, Grillari J, Gessl A, et al. (1995) 
High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 44: 
1323-1327.
32. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H (2013) Prognostic value of 
plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J 
Neuroendocrinol 25: 771-778.
33. Teichberg VI, Cohen KMK, Cooper I, Zlotnik A (2009) Homeostasis of 
glutamate in brain fluids: an accelerated brain-to-blood efflux of excess 
glutamate is produced by blood glutamate scavenging and offers protection 
from neuropathologies. Neuroscience 158: 301-308.
34. Boyko M, Zlotnik A, Gruenbaum BF, Gruenbaum SE, Ohayon S, et al. (2011) 
Pyruvate’s blood glutamate scavenging activity contributes to the spectrum of 
its neuroprotective mechanisms in a rat model of stroke. Eur J Neurosci 34: 
1432-1441.
35. Boyko M, Stepensky D, Gruenbaum BF, Gruenbaum SE, Melamed I, et al. 
(2012) Pharmacokinetics of glutamate-oxaloacetate transaminase and 
glutamate-pyruvate transaminase and their blood glutamate-lowering activity in 
naive rats. Neurochem Res 37: 2198-2205.
36. Wang J, Ning R, Wang Y (2016) Plasma D-dimer Level, the Promising 
Prognostic Biomarker for the Acute Cerebral Infarction Patients. J Stroke 
Cerebrovasc Dis 25: 2011-2015.
37. Matsumoto M, Sakaguchi M, Okazaki S, Furukado S, Tagaya M, et al. (2013) 
Relationship between plasma (D)-dimer level and cerebral infarction volume in 
patients with nonvalvular atrial fibrillation. Cerebrovasc Dis 35: 64-72.
38. Yuan W, Shi ZH (2014) The relationship between plasma D-dimer levels and 
outcome of Chinese acute ischemic stroke patients in different stroke subtypes. 
J Neural Transm 121: 409-413.
39. Bunevicius A, Kazlauskas H, Raskauskiene N, Janusonis V, Bunevicius R 
(2014) Ischemic stroke functional outcomes are independently associated with 
C-reactive protein concentrations and cognitive outcomes with triiodothyronine 
concentrations. A pilot study Endocrine 45: 213-220.
40. Suda S, Muraga K, Kanamaru T, Okubo S, Abe A, et al. (2016) Low free 
triiodothyronine predicts poor functional outcome after acute ischemic stroke. 
J Neurol Sci 368: 89-93.
Page 8 of 8
Cardiovasc Pharm Open Access journal
ISSN: 2329-6607
Citation: De Waele S, Hachimi-Idrissi S (2017) The Link between Early Biomarker Analysis and the Neurological Outcome in Stroke Patients. 
Cardiovasc Pharm Open Access 6: 219. doi: 10.4172/2329-6607.1000219
Volume 6 • Issue 5 • 1000219
41. Ambrosius W, Kazmierski R, Gupta V, Warot AW, Adamczewska KD, et al. 
(2011) Low free triiodothyronine levels are related to poor prognosis in acute 
ischemic stroke. Exp Clin Endocrinol Diabetes 119: 139-143.
42. Liu J, Wang D, Xiong Y, Yuan R, Tao W, et al. (2016) Low free triiodothyronine 
levels are related to symptomatic intracranial hemorrhage and poor functional
outcomes after intravenous thrombolysis in acute ischemic stroke patients.
Neurol Res 38: 429-433.
43. Ma L, Zhu D, Jiang Y, Liu Y, Ma X, et al. (2016) Low triiodothyronine: A new 
facet of inflammation in acute ischemic stroke. Clin Chim Acta 458: 63-67.
44. Neidert S, Katan M, Schuetz P, Fluri F, Ernst A, et al. (2011) Anterior pituitary axis 
hormones and outcome in acute ischaemic stroke. J Intern Med 269: 420-432.
45. Zi WJ, Shuai J (2013) Cortisol as a prognostic marker of short-term outcome in 
chinese patients with acute ischemic stroke. PLoS One 8: e72758.
46. Katan M, Elkind MS (2011) Inflammatory and neuroendocrine biomarkers of 
prognosis after ischemic stroke. Expert Rev Neurother 11: 225-239.
47. Bustamante A, Garcia BT, Llombart V, Simats A, Giralt D, et al. (2014) 
Neuroendocrine hormones as prognostic biomarkers in the setting of acute
stroke: overcoming the major hurdles. Expert Rev Neurother 14: 1391-1403.
48. Barugh AJ, Gray P, Shenkin SD, MacLullich AM, Mead GE (2014) Cortisol 
levels and the severity and outcomes of acute stroke: a systematic review. J 
Neurol 261: 533-545.
49. Katan M, Fluri F, Schuetz P, Morgenthaler NG, Zweifel C, et al. (2010) 
Midregional pro-atrial natriuretic peptide and outcome in patients with acute
ischemic stroke. J Am Coll Cardiol 56: 1045-1053.
50. Fischer M, Katan M, Morgenthaler NG, Seiler M, Müller B, et al. (2014). The 
prognostic value of midregional proatrial natriuretic peptide in patients with
hemorrhagic stroke Cerebrovasc Dis 37: 128-133.
51. Berntsson J, Zia E, Borné Y, Melander O, Hedblad B, et al. (2014) Plasma 
natriuretic peptides and incidence of subtypes of ischemic stroke. Cerebrovasc 
Dis 37: 444-450.
52. Sonderer J, Katan KM (2015) Aetiological blood biomarkers of ischaemic 
stroke. Swiss Med Wkly 145: 14138.
53. Abubakar S, Okubadejo N, Ojo O, Oladipo O, Ojini F, et al. (2013) Relationship 
between admission serum C-reactive protein and short term outcome following 
acute ischaemic stroke at a tertiary health institution in Nigeria. Niger J Clin 
Pract 16: 320-324.
54. Gröschel K, Schnaudigel S, Edelmann F, Niehaus CF, Weber KM, et al. (2012) 
Growth-differentiation factor-15 and functional outcome after acute ischemic 
stroke. J Neurol 259: 1574-1579.
55. Worthmann H, Kempf T, Widera C, Tryc AB, Goldbecker A, et al. (2011). 
Growth differentiation factor 15 plasma levels and outcome after ischemic 
stroke. Cerebrovasc Dis 32:72-78.
56. Brouns R, Wauters A, De Surgeloose D, Mariën P, De Deyn PP (2011) 
Biochemical markers for blood-brain barrier dysfunction in acute ischemic 
stroke correlate with evolution and outcome. Eur Neurol 65: 23-31.
57. Mendioroz M, Fernández CI, Rosell A, Delgado P, Domingues MS, et al. 
(2011). Osteopontin predicts long-term functional outcome among ischemic 
stroke patients. J Neurol. 258: 486-493.
58. Deng WJ, Shen RL, Li M, Teng JF (2015) Relationship between procalcitonin 
serum levels and functional outcome in stroke patients. Cell Mol Neurobiol 35:
355-361.
59. Huang JM, Hu J, Chen N, Hu ML (2013) Relationship between plasma high-
mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit 
Care 28: 792-797.
60. Bonifacic D, Toplak A, Benjak I, Tokmadzic VS, Lekic A, et al. (2016) Monocytes and
monocyte chemoattractant protein 1 (MCP-1) as early predictors of disease outcome 
in patients with cerebral ischemic stroke. Wien Klin Wochenschr 128: 20-27.
61. Carbone F, Vuilleumier N, Burger F, Roversi G, Tamborino C, et al. (2015). 
Serum osteopontin levels are upregulated and predict disability after an
ischaemic stroke. Eur J Clin Invest 45: 579-586.
62. Feng P, Niu X, Hu J, Zhou M, Liang H, et al. (2013) Relationship of serum 
magnesium concentration to risk of short-term outcome of acute ischemic
stroke. Blood Press 22: 297-301.
63. Chiquete E, Ruiz SJL, Murillo BLM, Arauz A, Orozco VDR, et al. (2013). Serum 
uric acid and outcome after acute ischemic stroke: Premier study. Cerebrovasc 
Dis 35: 168-174.
64. Marousi SG, Theodorou GL, Karakantza M, Zampakis P, Papathanasopoulos 
P, et al. (2010) Acute post-stroke adiponectin in relation to stroke severity, 
progression and 6 month functional outcome. Neurol Res 32: 841-844.
65. Arsalan IM, Khattak MB, Khan F, Anwar MJ (2011) Prognostic significance of 
serum bilirubin in stroke. J Ayub Med Coll Abbottabad 23: 104-107.
66. Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D, et al. 
(2010) The decrease in procarboxypeptidase U (TAFI) concentration in acute 
ischemic stroke correlates with stroke severity, evolution and outcome. J 
Thromb Haemost 8: 75-80.
67. Zweifel C, Katan M, Schuetz P, Ernst A, Mariani L, et al. (2011) Growth 
hormone and outcome in patients with intracerebral hemorrhage: a pilot study. 
Biomarkers 16: 511-516.
68. Tang JH, Ma LL, Yu TX, Zheng J, Zhang HJ, et al. (2014) Insulin-like growth 
factor-1 as a prognostic marker in patients with acute ischemic stroke. PLoS 
One 9: e99186.
69. Wang HC, Lin WC, Yang TM, Lin YJ, Tsai NW, et al. (2011). The association 
between symptomatic delayed cerebral infarction and serum adhesion molecules
in aneurysmal subarachnoid haemorrhage. Neurosurgery 68: 1611-1617.
70. Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, et al. (2010) 
Prognostic value of copeptin: one-year outcome in patients with acute stroke. 
Stroke 41: 1564-1567.
71. Azarpazhooh MR, Mobarra N, Parizadeh SMR, Tavallaie S, Bagheri M, et al. 
(2010). Serum High-Sensitivity C-Reactive Protein and Heat Shock Protein 27 
Antibody Titers in Patients With Stroke and 6-Month Prognosis. Angiology 61: 
607-612.
72. Rainer TH, Leung LY, Chan CPY, Leung YK, Abrigo JM, et al. (2016) Plasma 
miR-124-3p and miR-16 concentrations as prognostic markers in acute stroke. 
Clin Biochem 49: 663-668.
73. Xie S, Lu L, Liu L, Bi G, Zheng L (2016) Progranulin and short-term outcome in 
patients with acute ischaemic stroke. Eur J Neurol 23: 648-655.
74. Navarro SM, Rosell A, Hernández GM, Penalba A, Boada C, et al. (2011). 
A large screening of angiogenesis biomarkers and their association with
neurological outcome after ischemic stroke. Atherosclerosis 216: 205-211.
Citation: De Waele S, Hachimi-Idrissi S (2017) The Link between Early 
Biomarker Analysis and the Neurological Outcome in Stroke Patients. 
Cardiovasc Pharm Open Access 6: 219. doi: 10.4172/2329-6607.1000219
